A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants
NCT05909852
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
372
Enrollment
INDUSTRY
Sponsor class
Conditions
Adalimumab
Interventions
DRUG:
ABP 501-HCF
DRUG:
ABP 501-LCF
Sponsor
Amgen